What Is Sickle Cell Disease? Genetics, Symptoms, and Treatment

The Genetic Basis of Sickle Cell Disease

Sickle cell disease (SCD) is caused by a single point mutation in the HBB gene, which encodes the beta-globin subunit of hemoglobin—the oxygen-carrying protein in red blood cells. This mutation substitutes valine for glutamic acid at position 6 of the beta-globin chain, producing an abnormal form called hemoglobin S (HbS). Sickle cell disease is autosomal recessive, meaning an individual must inherit one copy of the HbS mutation from each parent to develop the disease (genotype HbSS, the most common and severe form, also called sickle cell anemia).

Other forms of SCD arise from compound heterozygosity—inheriting HbS from one parent and a different beta-globin mutation from the other. HbSC disease (one HbS and one HbC mutation) and HbS/beta-thalassemia are the most common compound heterozygous forms, typically producing milder-to-moderate disease compared with HbSS. The HbS mutation is most prevalent in populations from sub-Saharan Africa, the Mediterranean, the Middle East, and India—geographic regions where malaria has historically been endemic. Heterozygous carriers (HbAS, or 'sickle cell trait') have one normal beta-globin gene and one HbS gene; they do not have sickle cell disease and are generally healthy, but their red blood cells provide relative protection against severe falciparum malaria, explaining the evolutionary persistence of the mutation in malaria-endemic regions.

How HbS Causes Red Blood Cell Sickling

Under conditions of low oxygen tension (hypoxia), HbS molecules polymerize—forming long, rigid chains within the red blood cell. This polymerization distorts the normally biconcave, flexible red blood cell into a rigid, crescent (sickle) shape. Sickled red blood cells have several pathological properties: they are rigid and cannot deform to squeeze through narrow capillaries; they have a shortened lifespan of 10–20 days compared with the normal 120 days (causing chronic hemolytic anemia); and they adhere abnormally to the vascular endothelium, promoting vessel obstruction and inflammatory activation.

The polymerization process is reversible when oxygen levels normalize—red blood cells can unsickle and resickle repeatedly, but each cycle causes membrane damage that eventually renders the deformation irreversible. Multiple factors trigger or worsen sickling: hypoxia, acidosis, dehydration, cold temperatures, infection, and physical or emotional stress. Fetal hemoglobin (HbF)—the form of hemoglobin present in newborns—does not contain beta-globin and therefore cannot polymerize with HbS. Individuals with naturally higher HbF levels have a milder clinical course, a key biological insight that has shaped treatment strategies.

Clinical Manifestations

The vaso-occlusive pain crisis (VOC) is the hallmark of SCD and the most common cause of emergency department visits and hospitalizations. When sickled cells obstruct microvascular blood flow, the resulting ischemia (tissue oxygen deprivation) causes intense, acute pain—most commonly in the bones, chest, abdomen, and joints. VOCs can last days to weeks and range from mild (manageable at home) to severe (requiring intravenous opioids). Over a lifetime, repeated ischemia causes cumulative organ damage including avascular necrosis of the femoral head, stroke (including silent cerebral infarcts detectable only on MRI), and chronic organ dysfunction.

Acute chest syndrome (ACS) is a life-threatening complication defined as a new pulmonary infiltrate on chest X-ray combined with one or more of: fever, respiratory symptoms (cough, chest pain, wheezing), or hypoxia. ACS results from fat embolism (from infarcted bone marrow), infection, or in-situ sickling in the pulmonary microvasculature. It is the leading cause of death in SCD and requires urgent treatment including exchange transfusion. Other serious complications include splenic sequestration crises (rapid pooling of blood in the spleen causing life-threatening anemia, particularly in young children), priapism, retinopathy, renal disease, pulmonary hypertension, and chronic pain from ongoing organ damage.

Treatment: Hydroxyurea, Transfusions, and New Therapies

Hydroxyurea is a disease-modifying medication that dramatically reduces the frequency of VOCs and ACS. Its primary mechanism is increasing fetal hemoglobin (HbF) production—HbF interferes with HbS polymerization, reducing sickling. Hydroxyurea also reduces white blood cell and platelet counts, decreasing the adhesiveness that contributes to vascular occlusion, and increases red blood cell volume. The landmark BABY HUG trial established its safety and benefit even in infants as young as 9 months. Despite its proven efficacy, hydroxyurea remains underutilized due to barriers including concerns about long-term effects (which have proven unfounded in decades of follow-up) and medication adherence challenges.

Red blood cell transfusions are used acutely (for ACS, severe anemia, stroke) and chronically (as transfusion programs to prevent recurrent stroke in children identified as high-risk by transcranial Doppler ultrasound screening). Hematopoietic stem cell transplantation (HSCT) from a matched sibling donor is the only established curative treatment but is limited by donor availability and transplant-related risks. The most transformative recent development is gene therapy: Casgevy, approved in 2023 by the FDA and UK MHRA, uses CRISPR-Cas9 gene editing to reactivate fetal hemoglobin production in a patient's own stem cells—the first approved CRISPR therapy in humans. Lyfgenia (betibeglogene gene therapy) introduces functional beta-globin genes. These gene therapies offer the prospect of a functional cure for patients without matched donors, though cost (several million dollars per treatment) and accessibility remain enormous challenges.